Navigation Links
HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter
Date:1/18/2013

Ponte Vedra Beach, Florida (PRWEB) January 18, 2013

Today’s Newsletter from HealthEconomics.Com covers a fascinating overview of the history of evidence-based medicine (EBM), and describes the role of the patient in interpreting and applying EBM to their own health care. The article also discusses the physician’s dilemma of choosing either an evidence-based treatment plan that is based on population impact or one that predominantly considers the individual patient. Which is correct? The original article was sourced from the January issue of the American Medical Association Journal of Ethics.

Are drug price cuts to achieve reimbursement in the United Kingdom actually undermining pharma’s value story for their drug products, or is this tactic helping to bolster the cost-effectiveness story? Another top story reports Lucentis (ranibizumab) for impaired sight in some patients with diabetic macular edema has now won the backing of NICE, after the makers of the drug agreed to discount the price and provide additional evidence of efficacy. The story, originally published by Bloomberg, is covered in HealthEconomics.Com News.

How is the second Obama Administration going to affect healthcare access, payment reform, Medicare, Medicaid, healthcare quality initiatives, and the pharmaceutical industry? In an article by PharmaPro.Com, key issues are outlined. Some challenges pre-date the Affordable Care Act (ACA) and others have been caused by the passage of the ACA. Challenges include an undetermined impact of the individual mandate, reduced patient access to physicians, increased medical care wait times, and expansion of state Medicaid programs. The steps that the pharmaceutical industry needs to take to succeed in this post-election arena are detailed in this article on HealthEconomics.Com.

About HealthEconomics.Com: A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.
News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by clicking on the following link: Subscribe to HealthEconomics.Com Newsletter.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10332724.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
6. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
7. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
8. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
9. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
10. Fusion presents low proliferation risk, experts conclude
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), ... fourth quarter and full year ended December 31, ... for Vanda as we continued to demonstrate strong ... exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., ... pipeline with important 2017 milestones underscores Vanda,s commitment ...
(Date:2/15/2017)... Feb. 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, will ... presentation) at 8:00 AM EST on Thursday, February 16, ... clinical program, the recently announced closing of a $10.5 ... To participate in the live call and ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health ... Diameter Health technology in the hands of Lantana analysts. The high-performance platform of ... and public health entities – all those mining value from clinical data – ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):